Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KRIYA-839
- Development stage
- Preclinical
- Lead developer
- Kriya Therapeutics
- Modality
- Gene Therapies
- Administration
- Intramuscular
01
Overview
KRIYA-839 is an adeno-associated virus (AAV)-based gene therapy being developed by Kriya Therapeutics for the treatment of Type 1 diabetes. Designed as a one-time intramuscular injection, the therapy delivers genetic sequences encoding both insulin and glucokinase. The objective is to enable durable glycemic control by promoting the endogenous production of these proteins, thereby improving time-in-range and lowering HbA1c levels. Preclinical studies in streptozotocin-induced diabetic mice have shown that KRIYA-839 can potentially reduce or eliminate the requirement for exogenous insulin injections, aiming for insulin independence.
02
Targets
GCK (Glucokinase)
Beyond the preview
Go deeper on KRIYA-839.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KRIYA-839.